Scintigraphy with Octreotide is a useful procedure allowing identification of patients in the active phase of the ophthalmopathy who are likely to respond well to treatment with somatostatin analogues.
The presence of a paralysis of accommodation, with bilateral mydriasis that reacts to pilocarpine, makes it necessary to consider botulism as a possible cause.
RESUMENCaso clínico: Se presenta la evolución de un paciente con oftalmopatía de Graves (OG) tratado con análogos de la somatostatina, así como las indicaciones, pauta y resultados obtenidos. Discusión: Son pocas las opciones terapéuticas efectivas para el manejo de la oftalmopatía asociada a disfunción tiroidea de origen autoinmune. Los análogos de la somatostatina inhiben la proliferación y activación de los linfocitos, y se acumulan en el tejido orbitario durante la fase activa de la enfermedad oftálmica. Así, nos permitieron en el caso presentado llegar a la fase inactiva de la enfermedad sin secuelas importantes.Palabras clave: Análogos de la somatostatina, lanreótido, SOM230, enfermedad de Graves, octreoscan.
COMUNICACIÓN CORTA
ABSTRACTCase report: The effect of a somatostatin analogue in a patient with Graves' ophthalmopathy is presented, including data on the dose requirements and the results of therapy. Discussion: There are few effective options for the management of Graves' ophthalmopathy, a cellmediated immune co-morbidity of thyroid disease. Somatostatin analogues inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue during the active ophthalmopathy. Because of this, such therapy is able to inactivate the ophthalmopathy without complications occurring (Arch Soc Esp Oftalmol 2007; 82: 51-54).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.